Back to Browse Journals » Vascular Health and Risk Management » Volume 4 » Issue 2

Vascular risk factors, cognitve decline, and dementia

Authors E Duron, Olivier Hanon

Published Date May 2008 Volume 2008:4(2) Pages 363—381

DOI http://dx.doi.org/10.2147/VHRM.S1839

Published 6 May 2008

E Duron, Olivier Hanon

Broca Hospital, Paris, France

Abstract: Dementia is one of the most important neurological disorders in the elderly. Aging is associated with a large increase in the prevalence and incidence of degenerative (Alzheimer’s disease) and vascular dementia, leading to a devastating loss of autonomy. In view of the increasing longevity of populations worldwide, prevention of dementia has turned into a major public health challenge. In the past decade, several vascular risk factors have been found to be associated with vascular dementia but also Alzheimer’s disease. Some longitudinal studies, have found significant associations between hypertension, diabetus mellitus, and metabolic syndrome, assessed at middle age, and dementia. Studies assessing the link between hypercholesterolemia, atrial fibrillation, smoking, and dementia have given more conflicting results. Furthermore, some studies have highlighted the possible protective effect of antihypertensive therapy on cognition and some trials are evaluating the effects of statins and treatments for insulin resistance. Vascular risk factors and their treatments are a promising avenue of research for prevention of dementia, and further long-term, placebo-controlled, randomized studies, need to be performed.

Keywords: dementia, hypertension, diabetus mellitus, hypercholesterolemia, metabolic syndrome

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Chemotherapeutic potential of curcumin-bearing microcells against hepatocellular carcinoma in model animals

Farazuddin M, Dua B, Zia Q, Khan AA, Joshi B, Owais M

International Journal of Nanomedicine 2014, 9:1139-1152

Published Date: 3 March 2014

Risk factor investigation for cardiovascular health through WHO STEPS approach in Ardabil, Iran

Sadeghi-Bazargani H, Jafarzadeh H, Fallah M, Hekmat S, Bashiri J, Hosseingolizadeh GH, Soltanmohammadzadeh MS, Mortezazadeh A, Shaker A, Danehzan M, Zohouri A, Khosravi O, Nasimidoust R, Malekpour N, Kharazmi E, Babaei M, Nadirmohammadi M, Mashhadi-Abdoll H

Vascular Health and Risk Management 2011, 7:417-424

Published Date: 11 July 2011

Managing hypercholesterolemia and its correlation with carotid plaque morphology in patients undergoing carotid endarterectomy

Kittipan Rerkasem, Patrick J Gallagher, Robert F Grimble, Philip C Calder, Clifford P Shearman

Vascular Health and Risk Management 2008, 4:1259-1264

Published Date: 12 September 2008

A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes

Mozhgan Dorkhan, Anders Frid

Vascular Health and Risk Management 2007, 3:721-731

Published Date: 20 November 2007

Role of the vasodilator peptide angiotensin-(1–7) in cardiovascular drug therapy

Christoph Schindler, Peter Bramlage, Wilhelm Kirch, Carlos M Ferrario

Vascular Health and Risk Management 2007, 3:125-137

Published Date: 18 May 2007